AMA oncotype prostate cancer testing
Ended Awarded Last action
- Contract number
- 36C25724N0276
- Awardee
-
Mdxhealth, Inc. UEI LQGYDJJ9K8Q6
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $9,579
Award facts
- Contract value 100% obligated
- $9,578.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Irvine, CA 92618, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$18,079 | |
| Original award | $27,658 |
About this award
Mdxhealth, Inc. was awarded a $9,578.79 firm fixed price call under a Blanket Purchase Agreement with Veterans Integrated Service Network 17 (VISN 17) on April 3, 2024, for AMA Oncotype Prostate Cancer Testing services. The work will be performed at Mdxhealth's facility in Irvine, California, with an ultimate completion date of April 2, 2025. This call order falls under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), a General Services Administration vehicle that streamlines procurement of laboratory diagnostic services for the Department of Veterans Affairs. The contract does not contain a small business set-aside designation, allowing Mdxhealth to compete as a standard commercial vendor.
This award represents a delivery order against Mdxhealth's larger BPA vehicle with VISN 17, which was established on May 1, 2023, with a $4.8 million ceiling and a five-year performance period through April 30, 2028, for Oncotype DX prostate testing services. Mdxhealth maintains an established federal contracting presence with the VA's Veterans Health Administration across multiple VISNs, providing specialized molecular diagnostic and genomic testing capabilities for prostate and other cancer types. The company's core offering of advanced cancer diagnostic testing directly supports the VA's mission to deliver personalized, evidence-based healthcare to the veteran population through genomic biomarker analysis and treatment planning capabilities.
Quick answers
Who was awarded contract 36C25724N0276?
36C25724N0276 was awarded to Mdxhealth, Inc. by Veterans Integrated Service Network 17 (Veterans Health Administration) on April 3, 2024.
How much is contract 36C25724N0276 worth?
The government has obligated $9,579 on 36C25724N0276.
Is contract 36C25724N0276 an order under another contract?
Yes. 36C25724N0276 is a BPA call under V797D70066-36C25724A0020, a blanket purchase agreement, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract 36C25724N0276 competed?
The extent of competition for 36C25724N0276 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award